8mg retatrutide Diarrhea: Rates, Causes & Management Retatrutide: What It Is &

Tirzepatide expanded indications: Following FDA approvals in 20242025, tirzepatide (Zepbound/Mounjaro) has expanded labeling covering additional cardiovascular and metabolic indications

Over 412 weeks, doses increase incrementallytypically to 0.5 mg, then 1.0 mg, and potentially higheruntil reaching an effective maintenance level for your individual metabolism

The peptide carries 2-aminoisobutyric acid substitutions at positions 2 and 20 to resist dipeptidyl peptidase-4 degradation, a C-terminal amide, an N6-substituted lysine C18-diacid fatty acyl side chain for albumin binding and half-life extension, and a 2-methyl leucine substitution for selectivity tuning

Instead, they all had significant knee osteoarthritis